Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | SEC'Y; CHIEF COMPLIANCE & G.C. | February 28, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date February 28, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,190 |
Reported balance
After 2025-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-28 · Sale · Disposed 163 · Balance 7,190 F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Mar 4, 2025 21:58 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 163 | $4.76 | $775.88 |
DisclosureSEC source: 0001415889-25-006575 · form4-03042025_090329.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · SEC'Y; CHIEF COMPLIANCE & G.C. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,190 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 20:21 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,753 | $0.83 | $2,284.99 |
DisclosureSEC source: 0001415889-24-010569 · form4-04092024_080453.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · SEC'Y; CHIEF COMPLIANCE & G.C. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,247 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:24 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,293 | $0.89 | $2,930.77 |
DisclosureSEC source: 0001415889-24-006282 · form4-03042024_090307.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · SEC'Y; CHIEF COMPLIANCE & G.C. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002536 · form4-02052024_090253.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · SEC'Y; CHIEF COMPLIANCE & G.C. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,063 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 20:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,483 | $3.51 | $8,715.33 |
DisclosureSEC source: 0001209191-23-039884 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,563 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,481 | $4.91 | $12,181.71 |
DisclosureSEC source: 0001209191-23-023607 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,046 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.84 to $4.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:44 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 6,256 | $9.71 | $60,745.76 |
DisclosureSEC source: 0001209191-23-016790 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,527 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:38 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 81,000 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001209191-23-015577 · doc4.xml · derivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 08, 2023 Filed Feb 12, 2024 22:16 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 7,770 | $0.53 | $4,118.10 |
DisclosureSEC source: 0001415889-24-003408 · form4-02122024_100232.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · SEC'Y; CHIEF COMPLIANCE & G.C. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,293 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 21:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,561 | $11.27 | $28,862.47 |
DisclosureSEC source: 0001209191-22-062628 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,783 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on December 21, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,642 | $11.91 | $19,556.22 |
DisclosureSEC source: 0001209191-22-023249 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,344 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on April 1, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 22:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,787 | $11.38 | $20,336.06 |
DisclosureSEC source: 0001209191-22-016431 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,986 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of performance-based RSUs reported in the Form 4 filed with the Securities and Exchange Commission on March 1, 2022, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013994 · doc4.xml · nonDerivative · entry 3 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,773 F3 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 28, 2022. The vested shares represents the last of three possible vesting events of the total number of shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-22-013994 · doc4.xml · derivative · entry 4 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-25 F4 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,972 | $10.29 | $20,291.88 |
DisclosureSEC source: 0001209191-22-013994 · doc4.xml · nonDerivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,440 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013994 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,412 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:28 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 11,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070805 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,412 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 22:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,759 | $14.20 | $24,977.80 |
DisclosureSEC source: 0001209191-21-054304 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,917 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 22:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 5,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053537 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,676 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 23:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001209191-21-024299 · doc4.xml · derivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-03-30 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30, 2021, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 23:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024299 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,342 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 22:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,090 | $17.98 | $55,558.20 |
DisclosureSEC source: 0001209191-21-018652 · doc4.xml · nonDerivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,342 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018652 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,432 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 02:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,004 | $19.33 | $77,397.32 |
DisclosureSEC source: 0001209191-21-014551 · doc4.xml · nonDerivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,432 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014551 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,436 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award. Read SEC document |
| December 30, 2020 Filed Dec 30, 2020 23:16 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,946 | $15.30 | $29,773.80 |
DisclosureSEC source: 0001209191-20-065582 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,436 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1). Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 23:42 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065407 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,382 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the third of four possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 22:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,721 | $15.56 | $42,338.76 |
DisclosureSEC source: 0001209191-20-025308 · doc4.xml · nonDerivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,382 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 22:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025308 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,103 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on April 17, 2020. The vested shares represent the total number of remaining shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:10 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001209191-20-013106 · doc4.xml · derivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2030-02-24 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 24, 2020, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:10 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013106 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,769 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 24, 2021, February 24, 2022 and February 24, 2023, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 00:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,980 | $17.05 | $67,859.00 |
DisclosureSEC source: 0001209191-19-059185 · doc4.xml · nonDerivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,769 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059185 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,749 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 29, 2019 Filed May 30, 2019 22:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,303 | $21.38 | $49,238.14 |
DisclosureSEC source: 0001209191-19-033519 · doc4.xml · nonDerivative · entry 2 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,416 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $21.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| May 28, 2019 Filed May 30, 2019 22:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033519 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,719 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on May 28, 2019. The vested shares represent one-third of the total number of shares subject to the award, and the remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018218 · doc4.xml · derivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:56 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,100 | $12.51 | $38,781.00 |
DisclosureSEC source: 0001209191-19-000405 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,386 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 - $12.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:19 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 9,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064405 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,486 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:37 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 46,500 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001209191-18-019407 · doc4.xml · derivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2028-03-09 F1 · derivative.exercise_date: The shares shall vest in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.